The graft-versus-leukemia effect (GVL) is the recognition and destruction of leukemia cells by donor-derived immune cells after allogeneic hematopoietic stem cell transplantation. It contributes to the prevention of relapse and helps explain why transplantation can produce durable remission even when the preparative treatment does not eliminate every malignant cell. GVL is a form of cancer immunotherapy arising from the transplanted immune system rather than solely from the direct effects of chemotherapy or radiation.
Biological basis
In allogeneic transplantation, blood-forming stem cells and accompanying immune cells come from another person. Following engraftment, donor-derived cells establish blood-cell production and progressively reconstitute the recipient’s immune system. Some donor immune cells can recognize residual leukemia cells as targets.
This activity involves several overlapping mechanisms:
- T-cell recognition. Donor T cells recognize molecular targets presented on recipient cells. These targets may include inherited differences between donor and recipient, known as minor histocompatibility antigens, as well as antigens associated with leukemia.
- Antigen presentation. Human leukocyte antigen (HLA) molecules display protein fragments to T cells. Matching major HLA markers does not eliminate all immune differences between donor and recipient.
- Natural killer cell activity. Donor natural killer cells can attack cells according to the balance of activating and inhibitory signals they receive. Their contribution depends on the disease and transplantation setting.
- Immune-mediated killing. Activated immune cells can destroy targets through cytotoxic granules and cell-death signaling pathways.
GVL does not necessarily involve recognition of a leukemia-specific antigen. Some immune responses target features shared by malignant and normal recipient cells, which helps explain the close relationship between antileukemic activity and tissue injury.
Evidence and historical development
The concept developed from experimental transplantation studies and subsequent clinical observations showing that donor immunity contributed to leukemia control beyond the effects of conditioning treatment.
Several findings support the existence of GVL:
- In some transplant populations, recipients who develop graft-versus-host disease have lower relapse rates than those who do not.
- Extensive removal of donor T cells from a graft can increase relapse risk in certain settings.
- Infusion of additional donor lymphocytes after transplantation can produce remission in some patients with recurrent leukemia.
- Reduced-intensity conditioning can be followed by sustained disease control, demonstrating that intensive direct destruction of leukemia cells is not the only mechanism underlying transplantation.
These observations do not mean that every immune reaction prevents relapse or that a stronger donor immune response necessarily improves survival. Antileukemic effects must be considered alongside treatment-related complications.
Relationship to graft-versus-host disease
GVL and graft-versus-host disease (GVHD) both arise from donor immune activity against recipient cells, but they describe different outcomes. GVL denotes activity against leukemia; GVHD denotes injury to nonmalignant recipient tissues, particularly the skin, gastrointestinal tract, and liver.
The two effects overlap but are not identical. GVL can occur without clinically apparent GVHD, while severe GVHD can cause substantial illness or death despite control of leukemia. Consequently, GVHD is not a necessary or desirable marker of successful antileukemic immunity.
Immunosuppression used to prevent or treat GVHD can also influence antileukemic responses. The relationship is not a simple trade-off: it varies with the immune pathways affected, treatment timing, graft composition, and underlying disease. Separating effective leukemia-directed immunity from damaging tissue-directed immunity remains a major objective of transplantation research.
Clinical significance
Contribution to transplantation outcomes
Allogeneic transplantation combines the effects of conditioning—usually chemotherapy, sometimes with radiation therapy—with donor-derived immune activity. The relative contribution of each varies.
GVL is particularly well established in chronic myeloid leukemia. It also contributes to disease control in acute myeloid leukemia and acute lymphoblastic leukemia, although susceptibility varies substantially. Rapid disease growth, a high leukemia burden, and mechanisms of immune escape can limit its effectiveness.
Related donor-mediated effects against lymphoma and multiple myeloma are generally described using the broader terms graft-versus-tumor or graft-versus-malignancy effect.
Donor lymphocyte infusion
Donor lymphocyte infusion introduces additional lymphocytes from the original donor after transplantation. It can strengthen donor immune activity and is used in selected circumstances to address relapse or evidence of impending relapse.
Its activity provides direct clinical evidence of GVL, but responses differ markedly among diseases. Important complications include GVHD and suppression of blood-cell production. Donor lymphocyte infusion is therefore distinct from a uniformly effective or leukemia-specific treatment.
Assessment and limitations
There is no single routine test that directly measures the entire GVL effect. Its contribution is inferred from disease response, relapse patterns, immune studies, and changes following immune-directed interventions.
Monitoring may include measurable residual disease testing and assessment of donor chimerism—the proportion of blood or marrow cells derived from the donor. These measurements describe different phenomena. Complete donor chimerism does not prove that every leukemia cell has been eliminated, and residual-disease testing does not directly quantify donor immune activity.
Leukemia can recur despite an established donor immune system. Escape mechanisms include loss or reduced expression of recognizable targets, altered antigen presentation, and suppression or dysfunction of antileukemic immune cells. In some relapses after HLA-mismatched transplantation, leukemia cells lose the mismatched HLA region that previously enabled donor recognition.
Research strategies seek to preserve or enhance leukemia-directed immunity while limiting GVHD, including selective graft manipulation and donor-derived cells directed against more restricted targets. Their benefits and risks depend on the particular approach and clinical setting.